期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肾癌靶向治疗研究进展 被引量：6

原文传递
导出
摘要 随着肾癌生物学和遗传学研究进展，对肿瘤细胞信号传导途径的研究不断深入，针对肿瘤特异性分子靶点设计的治疗方案具有治疗特异性强、效果显著、基本不损伤正常组织的优点。
作者 吴恭瑾 岳中瑾
机构地区 兰州大学第二医院泌尿外科
出处 《中华泌尿外科杂志》 CAS CSCD 北大核心 2009年第1期58-59,共2页 Chinese Journal of Urology
基金 国家自然科学基金资助项目（30571860）
关键词 靶向治疗 肾癌 肿瘤特异性 信号传导途径 癌生物学 肿瘤细胞 治疗方案 分子靶点
分类号 R737.11 [医药卫生—肿瘤]
  • 相关文献

参考文献20

  • 1Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med, 2002,347 : 1593-1603.
  • 2Pavlovich CP, Schmidt LS. Searching for the hereditary causes of renal-cell carcinoma. Nat Rev Cancer, 2004,4.. 381-393.
  • 3Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma. Cancer, 1997,80:987-989.
  • 4Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumorsuppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A, 1994,91 : 9700-9704.
  • 5Linehan WM. Molecular targeting of VHL gene pathway in clear cell kidney cancer. J Urol, 2003,170 : 593-594.
  • 6Fabian MA, Biggs WH, Trieber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotech ,2005,23:329-336.
  • 7Raymond E, Faivre S, Vera C. Final results of phase I and pharmokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced ancers. Proc Am Soc Clin Onco, 2003,122 : 192.
  • 8Motzer RJ, Michaelson MD, Redman BG, et al . SU11248, a multi-targeted inhibitor of vascular endothelial growth factor receptor and latelet-derived growth factor receptor, demonstrated antitumor activity in patients with metastatic renal cell carcinoma. J Clin Oncol, 2005,24 : 1-8.
  • 9John P. Phase III Study of sunitinib malate (SU11248) versus interferonalpha as first-line treatment in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer, 2006, 5:23-25.
  • 10Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res,2004,64:7099-7109.

二级参考文献20

  • 1Reya T, Morrison SJ, Clarke MF, et al. Stem cells,cancer,and cancer stem cells. Nature,2001,414 : 105-111.
  • 2Masters JR, Foley CL, Bisson I, et al. Cancer stem cells. BJU Int,2003,92:661-662.
  • 3Marx J. Mutant stem cells may seed cancer.Science ,2003,301 : 1308-1310.
  • 4Mackillop WJ, Ciampi A, Till JE, et al. A stem cell model of human tumor growth:implications for tumor cell clonogenic assays. J Natl Cancer Inst, 1983,70:9-16.
  • 5Bonnet D, Dick JE. human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med , 1997,3:730-737.
  • 6Al-Hjj M, Wicha MS, Benito-Hemandez A,et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA ,2003,100:3983-3988.
  • 7Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res, 2003,63 : 5821-5828.
  • 8Sharpless NE, DePinho RA. Telomeres, stem cells, senescence,and cancer. J Clin Invest,2004,113 : 160-168.
  • 9Dick JE. Breast cancer stem cells revealed.Proc Natl Acad Sci,2003,100:3547-3549.
  • 10Molofsky AV, Pardal R, lwashita T, et al.Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature ,2003,425:962-967.

共引文献4

同被引文献96

  • 1岳中瑾.肿瘤干细胞及肾癌相关研究进展[J].中华泌尿外科杂志,2005,26(8):573-575. 被引量：5
  • 2司徒杰,高新,湛海伦,温星桥,邱剑光.CIK细胞免疫疗法在肾癌治疗中的应用[J].白求恩军医学院学报,2005,3(4):215-216. 被引量：9
  • 3张宁,龚侃,杨新宇,辛殿旗,那彦群.缺氧诱导因子和血管内皮生长因子在非遗传性肾透明细胞癌中的表达及意义[J].中华医学杂志,2006,86(22):1526-1529. 被引量：8
  • 4宣寒青,黄翼然,刘东明,薛蔚,陈奇.von Hippel-Lindau抑癌基因在散发性肾透明细胞癌中的突变及其意义[J].中国癌症杂志,2007,17(6):453-456. 被引量：3
  • 5Costa LJ, Drabkin HA. Renal cell carcinoma:new developments in molecular biology and potential for targeted therapies [J]. Oncologist ,2007,12(12) :1404 - 1415.
  • 6Strumberg D,Richly H,Hilger RA,et al. Phase Ⅰ clinical and pharo macokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors[ J]. J Clin Oncol,2005,23 (5) :965 -972.
  • 7Ratain MJ ,Eisen T,Stadler WM,et al. Phase Ⅱ placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma[J]. J Clin Oncol,2006,24(16):2505-2512.
  • 8Escudier B,Szczylik C,Eisen T,et al. Randomized Phase Ⅲ trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma(RCC) [J]. J Clin Oncol,2005,23(16 Suppl) :380.
  • 9Akaza H ,Tsukamoto T, Murai M, et al. Phase Ⅱ study to investigate the efficacy, safety, and phamacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma[J]. Jpn J Clin Oncol, 2007,37 (10) :755 - 762.
  • 10Motzer R j, Bacik J, Murphy BA, et al. Interferon-alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma[J]. J Clin Oncol,2002,20( 1 ) :289 -296.

引证文献6

二级引证文献23

中华泌尿外科杂志
2009年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部